Back to results
US 5,846,827 AGranted
Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of CTL
AssigneeCytel Corporation
InventorsEsteban Celis, Ralph Kubo, Horacio Serra, Van Tsai, Peggy Wentworth
Life of this patent
Estimating the term…
Abstract
Methods for activating cytotoxic T lymphocytes (CTL) in vitro are presented in conjunction with methods for using the activated CTL for therapy in vivo. Additionally, a method for killing specific CTL in vivo is presented using antigen presenting cells which were modified in vitro.
Claims16
A method for activating cytotoxic T cells in vitro comprising:
- dissociating bound peptides from class I MHC molecules on antigen presenting cells, using a mild acid treatment;
- associating desired immunogenic peptides with the class I MHC molecules on the antigen presenting cells;
- and
- incubating the antigen presenting cells with the cytotoxic T cells in the presence of a growth factor, thereby producing activated cytotoxic T cells.
1 more element
A method of specifically killing target cells in a human patient, comprising:
- obtaining a fluid sample containing cytotoxic T cells from the patient;
- contacting the cytotoxic T cells with antigen presenting cells, wherein said antigen presenting cells are produced by the steps of:
- (a) dissociating bound peptides from the class I MHC molecules on said antigen presenting cells using a mild acid treatment;
- and
- (b) associating desired immunogenic peptides with said class I MHC molecules on said antigen presenting cells;
- thereby producing activated cytotoxic T cells;
- contacting the activated cytotoxic T cells with an acceptable carrier, thereby forming a pharmaceutical composition;
- and
- administering the pharmaceutical composition to a patient.
6 more elements
Dependencies are inferred from the claim text.